Klaria Pharma Holding AB (publ.) (FRA:6FN)

Market Cap	17.32M +217.7%
Revenue (ttm)	9.11K -99.1%
Net Income	-4.19M
EPS	-0.02
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	0.0652
Previous Close	0.0660
Day's Range	0.0652 - 0.0652
52-Week Range	0.0308 - 0.1185
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Jun 5, 2026

About FRA:6FN

Klaria Pharma Holding AB (publ.), a pharmaceutical company develops and commercializes medication for migraine and cancer related pain, and opioid overdose and anaphylactic shock. Its product pipeline includes Sumatriptan, a novel the treatment of migraine which is in final stage of approval; Epinephrine/Adrenaline which is in Phase I clinical trial for the treatment of acute allergic reaction. The company also offers Sirolimus which is in pre-clinical stage for prevention of organ transplant rejection. In addition, it is involved in commercial...

• Industry: Pharmaceutical Preparations
• Founded: 2014
• Employees: 4
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 6FN

Financial Performance

In 2025, FRA:6FN's revenue was 8.99 million, an increase of 299.69% compared to the previous year's 2.25 million. Losses were -47.06 million, -1.45% less than in 2024.

Financial numbers in SEK

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Jun 26, 2026

Data Sources Report a data error